Literature DB >> 2445079

Orthotopic liver transplantation in dogs receiving FK-506.

S Todo1, L Podesta, P ChapChap, D Kahn, C E Pan, Y Ueda, K Okuda, O Imventarza, A Casavilla, A J Demetris.   

Abstract

Ten dogs that survived the perioperative events of liver transplantation were treated with 1 mg/kg/d oral FK. Eight of the recipients lived for at least 1 month postoperatively, and seven are still alive with normal hepatic function after 35 to 65 days. The consistency and good quality of results with this difficult transplant preparation using FK, in spite of its rumored great toxicity in dogs, have highlighted the importance of further developing the drug.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2445079      PMCID: PMC2903858     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  3 in total

1.  Effect of a new immunosuppressive agent, FK 506, on heterotopic cardiac allotransplantation in the rat.

Authors:  T Ochiai; K Nakajima; M Nagata; T Suzuki; T Asano; T Uematsu; T Goto; S Hori; T Kenmochi; T Nakagoori
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

2.  IMMUNOSUPPRESSION WITH FR 900506 FOR CANINE KIDNEY AND LIVER TRANSPLANTATION.

Authors:  S Todo; L Makowka; T Starzl
Journal:  Surg Res Commun       Date:  1987-01-01

3.  Canine liver transplantation under Nva2-cyclosporine versus cyclosporine.

Authors:  S Todo; K A Porter; I Kam; S Lynch; R Venkataramanan; A DeWolf; T E Starzl
Journal:  Transplantation       Date:  1986-03       Impact factor: 4.939

  3 in total
  28 in total

Review 1.  Advances in the development of immunosuppressive agents in organ transplantation.

Authors:  T Ochiai; K Isono
Journal:  Surg Today       Date:  1997       Impact factor: 2.549

2.  History of clinical transplantation.

Authors:  T E Starzl
Journal:  World J Surg       Date:  2000-07       Impact factor: 3.352

3.  Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction.

Authors:  A C Tsamandas; S M Pham; E C Seaberg; O Pappo; R L Kormos; A Kawai; B P Griffith; A Zeevi; R Duquesnoy; J J Fung; T E Starzl; A J Demetris
Journal:  J Heart Lung Transplant       Date:  1997-07       Impact factor: 10.247

4.  Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications.

Authors:  J J Fung; S Todo; A Jain; J McCauley; M Alessiani; C Scotti; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

5.  Gastrointestinal and metabolic problems associated with immunosuppression with either CyA or FK 506 in liver transplantation.

Authors:  D H Van Thiel; M Iqbal; A Jain; J Fung; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

6.  Pathologic observations in human allograft recipients treated with FK 506.

Authors:  A J Demetris; J J Fung; S Todo; B Banner; T Zerbe; G Sysyn; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

7.  The effect of FK 506 on small intestine allotransplantation in the rat.

Authors:  A L Hoffman; L Makowka; X Cai; B Banner; D V Cramer; A Pascualone; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

8.  Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy.

Authors:  K K Lee; M J Stangl; S Todo; J M Langrehr; T E Starzl; W H Schraut
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

9.  FK 506 versus cyclosporine in pediatric liver transplantation.

Authors:  A G Tzakis; J Reyes; S Todo; M Green; T Ohya; A Jain; K Abu-Elmagd; M Alessiani; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

10.  Suppression of autoimmune thyroid disease by FK 506: influence on thyroid-infiltrating cells, adhesion molecule expression and anti-thyroglobulin antibody production.

Authors:  K Tamura; J Woo; N Murase; G Carrieri; M A Nalesnik; A W Thomson
Journal:  Clin Exp Immunol       Date:  1993-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.